Obesity Is Not Associated with Impaired Immune Response to Influenza Vaccination in HIV-Infected Persons
Table 2
Proportions of participants with seroconversion and seroprotection after vaccination and pre- and postvaccination geometric mean titers of hemagglutination inhibition.
(a)
Nonobese (BMI < 30 kg/m2)
Obese (BMI ≥ 30 kg/m2)
value
()
()
Seroconversion, % (95% CI)
H1N1
70 (62–78)
62 (48–77)
0.32
H3N2
77 (69–84)
79 (67–91)
0.71
Influenza B
44 (35–52)
48 (33–63)
0.62
(b)
SD vaccine recipients
HD vaccine recipients
Nonobese
Obese
value
Nonobese
Obese
value
Seroconversion, % (95% CI)
H1N1
59 (47–72)
62 (39–84)
0.84
81 (71–91)
63 (43–82)
0.06
H3N2
75 (64–86)
71 (50–92)
0.74
78 (68–88)
85 (71–100)
0.44
Influenza B
34 (22–46)
29 (8–50)
0.62
53 (40–66)
63 (43–82)
0.39
Seroprotection, % (95% CI)
H1N1
86 (77–95)
90 (77–100)
0.59
98 (95–100)
89 (76–100)
0.04
H3N2
91 (83–98)
100 (100–100)
0.15
97 (92–100)
93 (82–100)
0.36
Influenza B
83 (73–92)
67 (45–89)
0.12
89 (81–97)
96 (89–100)
0.27
Prevaccination GMT (95% CI)
H1N1
20 (11–37)
22 (7–67)
0.90
17 (9–30)
59 (23–154)
0.02
H3N2
33 (20–55)
17 (6–48)
0.20
24 (13–43)
23 (10–54)
0.97
Influenza B
16 (10–26)
18 (8–38)
0.84
18 (11–30)
20 (11–37)
0.86
Postvaccination GMT (95% CI)
H1N1
307 (180–524)
386 (178–839)
0.66
684 (489–955)
746 (356–1570)
0.82
H3N2
322 (202–515)
338 (192–667)
0.92
681 (439–1057)
771 (409–1456)
0.75
Influenza B
63 (42–93)
60 (25–144)
0.92
149 (109–204)
122 (78–192)
0.48
BMI: body mass index; CI: confidence interval; GMT: geometric mean titer; HD: high dose; SD: standard dose.
